regeneron dna - Search News

Order byBest matchMost fresh

Regeneron Just Bought Your DNA From 23andMe

Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.

· 2d · on MSN

· 22h

Regeneron buying 23andMe; What happened to 23andMe? Should I delete 23andMe data?

· 2d · on MSN

Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million

23andMe to Be Bought by Biotech Company for $256 Million

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.

· 1d

23andMe Sold To Biotechnology Company For $256 Million

· 1d

23andMe sold to biotech company Regeneron for $256 million

Biotechnology company Regeneron buying 23andMe for $256 million

Privacy concerns related to customers’ genetic information have also emerged, notably spanning from a 2023 data breach — along with questions around what new ownership could mean for users’ data.

· 1d

· 9h

Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains

· 1d

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

2don MSN

23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.

2don MSN

23andMe Sells Gene-Testing Business to DNA Drug Maker Regeneron

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.

Stocktwits on MSN2d

Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts

Drugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology company 23andMe Holding Co. for $256 million. Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS),